Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial

Core Insights - Anixa Biosciences has completed dosing its final patient in the third cohort of a Phase 1 clinical trial for its CAR-T therapy targeting recurrent ovarian cancer, in partnership with Moffitt Cancer Center [1][4] - The third cohort received a dose of one million CAR-positive cells per kilogram, a tenfold increase from the first cohort, with the fourth cohort set to increase the dosage by another factor of three [2][3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is also developing vaccines for breast and ovarian cancer in partnership with Cleveland Clinic, targeting various cancers through innovative immunization strategies [5] Clinical Trial Details - The ongoing trial (NCT05316129) is designed to evaluate the safety and efficacy of the CAR-T therapy in adult women with recurrent ovarian cancer who have not responded to at least two prior therapies [3] - Recent protocol amendments allow eligible patients to receive a second dose without requiring separate IND approvals, expanding the enrollment criteria to include rare ovarian cancer subtypes [4]